



1. An isolated nucleic acid sequence which encodes biologically active ETF.
2. An isolated nucleic acid sequence according to claim 1 wherein said nucleic acid sequence is selected from the group consisting of:
 - (a) cDNA which encodes a mammalian ETF gene;
 - (b) nucleic acid sequences which hybridize to the cDNA of (a) under moderate stringency conditions and which encode a biologically active ETF; and
 - (c) nucleic acid sequences that are degenerate as a result of the genetic code to the nucleic acid sequences of (a) or (b), and which encode biologically active ETF.
3. An isolated nucleic acid sequence according to claim 1 wherein said ETF is human ETF.
4. An isolated nucleic acid sequence according to claim 1 wherein said nucleic acid sequence comprises nucleotides 145 through 486 of the DNA sequence of SEQ. ID. NO. 1.
5. An isolated nucleic acid sequence according to claim 1 wherein said nucleic acid sequence comprises nucleotide 145 through 486 of the DNA sequence of SEQ. ID. NO. 4.
20. A nucleic acid consisting essentially of at least 12 contiguous nucleotides from SEQ ID NO:1, SEQ ID NO:4, or the complementary sequences of SEQ ID NO:1 or SEQ ID NO:4.

RECEIVED

FEB 2 3 2001

TECH CENTER 1600/2900

21. The nucleic acid of claim 20 consisting essentially of 12 to about 75 contiguous nucleotides.
22. The nucleic acid of claim 21 consisting essentially of 12 to 14 nucleotides.
23. The nucleic acid of claim 21 consisting essentially of 14 to 18 nucleotides.
24. The nucleic acid of claim 21 consisting essentially of 18 to 20 nucleotides.
25. The nucleic acid of claim 21 consisting essentially of 20 to about 75 nucleotides.
26. The nucleic acid of claim 21 labeled with a radioactive, fluorescent, enzymatic, or chromogenic marker.
27. The nucleic acid of claim 21 wherein the nucleic acid is DNA.
28. The nucleic acid of claim 27 selected from the group consisting of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, and the complementary sequences of SEQ ID NO:9, SEQ ID NO:10, and SEQ ID NO:11.
29. The nucleic acid of claim 27 selected from the group consisting of SEQ ID NO:9, SEQ ID NO:10, and SEQ ID NO:11.
30. A composition comprising the nucleic acid of claim 21 and a diluent or carrier.
31. A method of detecting ETF in a sample comprising contacting the sample with the nucleic acid of claim 21.

32. A method of amplifying ETF in a sample comprising contacting the sample with the nucleic acid of claim 21.

33. A method of inhibiting the expression of ETF in a sample comprising contacting the sample with the nucleic acid of claim 21.